HAMBURG, GERMANY/ACCESSWIRE/June 14, 2022/ Evotec SE (FRA:EVT)(MDAX/TecDAX)(ISIN:DE0005664809)(NASDAQ:EVO) announced today that the company has entered into a drug discovery collaboration with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (“Janssen”). Evotec’s innovative targetHelloMod platforms will be evaluated to discover novel therapeutic candidates with novel modes of action. The deal was facilitated by Johnson & Johnson Innovation.

Under the agreement, Evotec and Janssen will jointly perform screens on identified targets and collaborate in the identification of hits and lead optimization of the most promising chemical assets, leveraging the integrated discovery platform and of Evotec’s end-to-end drug development.

Dr. Cord Dohrmann, Scientific Director of Evotec, commented: “We are very proud to enter into this collaboration to explore unique approaches towards high potential cell surface drug targets with new therapeutic modalities and to propose and make available to patients innovative therapeutic options.

In addition to research funding, Evotec is entitled to success-based research and commercial milestones of up to approximately €210 million per project as well as tiered royalties on products resulting from this collaboration.

About the targetHelloMod

Evotec scientists have discovered that for some extracellular receptors, small molecules can bind allosterically and induce a natural proteolytic cleavage process to remove the ectodomain. This results in the disruption of cell signaling and the loss ectodomain can, in many cases, additionally act as a sink for the native ligand of the targeted receptor. TargetHelloMod The platform includes a suite of proprietary assay principles and computational tools to assess and screen extracellular receptor targets for excretion and induction of excretion by small molecule allosteric modulators. This platform has wide applicability in many therapeutic areas.

The story continues

ABOUT EVOTEC SE

Evotec is a life sciences company with a unique business model that pursues its mission to discover and develop highly effective treatments and bring them to patients. The Company’s multi-modality platform includes a unique combination of innovative technology, data and science for the discovery, development and production of first-class, first-class pharmaceuticals. Evotec leverages this “data-driven R&D Highway to Cure” for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotech companies, academic institutions, as well as other health actors. Evotec has strategic activities in a wide range of currently underserved therapeutic areas, including neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world’s first pipeline of innovative co-owned therapeutics and has to date established a portfolio of over 200 proprietary and co-owned R&D projects, from early discovery to clinical development. Evotec operates worldwide with over 4,200 highly skilled people. The Company’s 15 sites offer highly synergistic technologies and services and operate as complementary centers of excellence. For more information, visit www.evotec.com and follow us on Twitter@Evotec and LinkedIn.

FORWARD-LOOKING STATEMENTS

This announcement contains forward-looking statements regarding future events, including the proposed offering and listing of Evotec’s securities. Words such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “intend”, “may”, “could”, “plan”, “potential”, “should”, “target”, ” ” and variations of these words and similar expressions are intended to identify forward-looking statements. These statements include comments regarding Evotec’s expectations for revenue, group EBITDA and non-partnership R&D expenditure. These forward-looking statements are based on available information and on expectations and assumptions that Evotec believed to be reasonable at the time such statements were made. No assurance can be given that these expectations will prove to be correct. These statements involve known and unknown risks and are based on a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond Evotec’s control. Evotec expressly disclaims any obligation or undertaking to publicly release any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec’s expectations with respect thereto or any change in events, conditions or circumstances about which any statement is based.

Evotec SE media contact:
Gabriele Hansen, SVP Head of Global Corporate Communications & Marketing, Phone: +49.(0)40.56081-255, [email protected]

Evotec SE IR contact:
Volker Braun, SVP Head of Global Investor Relations & ESG, Phone: +49.(0)40.56081-775, [email protected]

THE SOURCE: Evotec SE

See the source version on accesswire.com:
https://www.accesswire.com/705018/Evotec-Enters-a-Drug-Discovery-Collaboration-with-Janssen